GMAB

Genmab shares rallied 10.7% following positive phase III trial data for epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymphoma. The stock's consensus EPS estimate was revised 8.7% higher over the past 30 days, though earnings are expected to decline 43.1% year-over-year while revenues grow 15.7%. The stock carries a Zacks Rank #3 (Hold) rating.

Genmab and Incyte announced a Phase 1/2 clinical trial collaboration to evaluate petosemtamab combined with INCB161734 and standard-of-care chemotherapy as a first-line treatment for patients with KRAS G12D-mutated metastatic colorectal cancer. Genmab will conduct the study while Incyte will co-fund and provide clinical supply of INCB161734.

AbbVie and Genmab announced positive phase III EPCORE DLBCL-2 study results showing that epcoritamab combined with R-CHOP significantly improved progression-free survival compared to R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients, reducing disease progression or death risk by 51%. The combination was well tolerated with a safety profile consistent with prior reports.

The Nasdaq gained 1.05% to 27,477 as tech optimism drove market gains despite rising Treasury yields. The S&P 500 rose 0.66% and the Dow added 0.18%.

Key movers included Vaxcyte (up 30% on vaccine success), Genmab (up 11% on lymphoma drug data), and PTC (following a $22.6B buyout offer). Nvidia gained 2.12% amid speculation about reaching a $6 trillion market cap. Investors showed increased appetite for risk following softer-than-expected jobs data, reducing expectations for further Fed rate hikes.

Genmab and AbbVie announced positive Phase 3 trial results for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. The combination demonstrated a statistically significant 51% reduction in disease progression or death risk compared to R-CHOP alone, with a favorable safety profile. This marks the first Phase 3 study of a bispecific antibody combination to show significant improvement in progression-free survival in frontline DLBCL treatment.

Genmab announced Phase 2 results for Rina-S (rinatabart sesutecan) in platinum-resistant ovarian cancer, demonstrating a 45.9% objective response rate with a median duration of response of 12.1 months and median progression-free survival of 9.5 months. The drug showed antitumor activity regardless of folate receptor alpha expression levels, with manageable tolerability. The company is advancing four Phase 3 trials across multiple gynecologic cancers.

Darwin Global Management Limited has disclosed a significant shareholding in Genmab A/S, controlling 3,188,361 shares and ADRs representing 5.11% of voting rights as of September 28, 2026. The announcement was made under Danish Capital Markets Act requirements.

Genmab A/S announced the grant of 13,794 restricted stock units and 13,331 warrants to employees. The RSUs have a fair value of DKK 2,268 per unit and will vest after three years, while warrants have an exercise price of DKK 2,268 with a Black-Scholes fair value of DKK 781.96, vesting in three years and expiring after seven years.